Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q3 FY20 results · Oct–Dec 2019
Aarti Drugs reported revenue from operations of ₹473.51 crore (up 24.6% from Q3 FY19) and net profit of ₹27.78 crore (up 33.0% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 473.51 | 380.10 | +24.6% | 477.50 | −0.8% |
| Other income | 0.25 | 0.17 | +47.1% | 0.19 | +31.6% |
| Total income | 473.76 | 380.27 | +24.6% | 477.69 | −0.8% |
| Profit before tax | 43.08 | 30.83 | +39.7% | 47.86 | −10.0% |
| Net profit for the period | 27.78 | 20.89 | +33.0% | 32.31 | −14.0% |
| EPS, basic (₹) | 11.92 | 8.86 | +34.5% | 13.87 | −14.1% |
| Net margin (%) | 5.9 | 5.5 | 6.8 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 415.61 | 350.65 | +18.5% | 442.71 | −6.1% |
| Other income | 0.13 | 0.21 | −38.1% | 0.21 | −38.1% |
| Total income | 415.74 | 350.86 | +18.5% | 442.92 | −6.1% |
| Profit before tax | 39.50 | 31.05 | +27.2% | 45.80 | −13.8% |
| Net profit for the period | 26.75 | 21.15 | +26.5% | 30.80 | −13.1% |
| EPS, basic (₹) | 11.48 | 8.97 | +28.0% | 13.22 | −13.2% |
| Net margin (%) | 6.4 | 6.0 | 7.0 |
Consolidated
- Filed with BSE
- 07 Feb 2020, 14:03 IST
- Board meeting
- 06 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Feb 2020, 14:03 IST
- Board meeting
- 06 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Audited
- Source
- XBRL filing on BSE